Verona Pharma hints at COPD breakthrough with RPL554

10 May 2016
2019_biotech_test_vial_discovery_big

UK biotech Verona Pharma (LSE: VRP) has announced positive headline data from a Phase IIa study on the bronchodilator effect of nebulized RPL554, administered on top of salbutamol and ipratropium bromide, for chronic obstructive pulmonary disease (COPD).

The company believes this could address a multi-million dollar market in providing an answer for patients with COPD, the name for a collection lung conditions including chronic bronchitis, emphysema and chronic obstructive airways disease.

RPL554 is a new inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule. It is currently in development as a nebulized treatment for acute exacerbations in COPD patients in a hospital or for maintenance treatment in a home-care setting.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology